Elanco’s Breakthrough Treatment for Deadly Canine Parvovirus Has Saved Thousands of Puppies, Reaffirms Commitment to Increasing the Availability of Canine Parvovirus Monoclonal Antibody for Second Annual National Parvo Awareness Day

April 23, 2025 02:20 AM AEST | By 3BL
 Elanco’s Breakthrough Treatment for Deadly Canine Parvovirus Has Saved Thousands of Puppies, Reaffirms Commitment to Increasing the Availability of Canine Parvovirus Monoclonal Antibody for Second Annual National Parvo Awareness Day
Image source: Kalkine Media
  • National Parvo Awareness Day raises awareness of canine parvovirus (parvo), the often-fatal puppy disease.
  • Elanco’s Canine Parvovirus Monoclonal Antibody (CPMA) is the first-and-only USDA conditionally approved treatment for parvo.
  • Puppies treated with CPMA had a 93% survival rate and returned home an average of 1.87 days sooner.[1],[2]
  • Elanco’s ParvoTrack, the first-ever national online parvo tracking tool, allows pet owners and veterinarians to self-report outbreaks in real time, further highlighting the need for CPMA across the country and reinforcing Elanco’s commitment to increasing the availability of CPMA.
  • Texas, Arizona, Georgia, Florida, Illinois, Indiana and New York have some of the highest reported cases of canine parvovirus outbreaks according to ParvoTrack.

GREENFIELD, Ind., April 22, 2025 /3BL/ - Elanco Animal Health Incorporated (NYSE: ELAN) today recognizes the second annual National Parvo Awareness Day, aimed at increasing awareness of canine parvovirus, a highly contagious and often-fatal puppy disease. Since receiving conditional approval from the USDA, Canine Parvovirus Monoclonal Antibody (CPMA) has helped save thousands of puppies.[3] Although parvovirus can strike anytime, late spring and summer months are the most common for outbreaks nationwide.

“Parvo is a devastating disease that not only impacts our pets, but takes an emotional toll on pet owners, veterinarians and animal health experts,” said Dr. Chris George, veterinarian and infectious disease expert at Elanco Animal Health. “Without supportive care, parvo has a 91% mortality rate.[4] However, there’s a treatment beyond just supportive care – Elanco’s CPMA which can help defend puppies and defeat parvo. In real-world usage, 93% of parvo-infected puppies treated with CPMA survived.[1] Additionally, parvo patients treated with CPMA spend an average of 1.87 less days in the hospital, helping to relieve the emotional toll on treating veterinary staff and getting pets back with their families. CPMA is changing the way we treat parvo and is helping save puppies across the country.”[2]

Elanco’s mission to save 1 million puppies from parvovirus by 2030

"Making CPMA widely available is crucial in our fight against this devastating virus, including in shelter environments where resources are often strained,” said Bobby Modi, Executive Vice President, U.S. Pet Health. “Elanco is focused on increasing access to this life-saving treatment, and we’ve saved thousands of puppies in the first year[3] – but we need help from every clinic around the country to reach our mission of saving 1 million puppies from parvovirus by 2030. We believe every clinic and shelter should experience the power of CPMA firsthand, so we encourage clinics who haven’t tried it to learn more about how they can save their first parvo puppy using CPMA.”

Last year, Elanco launched ParvoTrack as the first-ever real-time online parvo tracking tool, empowering pet owners and the veterinary community with innovative intelligence to help notify them of parvo outbreaks in their communities. Visitors to the site can self-report and identify parvo outbreak areas, with a few simple steps, as well as sign up for parvo outbreak alerts in their area. Since launching ParvoTrack last year, thousands of parvo cases have been reported nationwide, with over 7,000 pet owners and veterinarians signing up to receive alerts with outbreaks in their area. ParvoTrack updates in real time and displays data from the past 12 months. Parvo outbreaks have occurred in every state with Texas, Arizona, Georgia, Florida, Illinois, Indiana and New York having some of the highest reported cases of canine parvovirus outbreaks.

“Every clinic and every shelter should have CPMA readily available.” 

“We’ve been treating parvo since early 2020 and it can be an absolutely devasting disease that weighs heavily on the staff,” said Dr. Meghan Herron, Senior Director of Behavior, Research, and Education at Gigi’s, an Ohio-based organization dedicated to improving the lives of shelter dogs. “Now that we have CPMA on board, everyone’s attitudes have changed. We no longer must fear a parvo outbreak because we have a treatment on hand that reduces hospitalization time and has a 93% survival rate. Every clinic and every shelter should have CPMA readily available.”

250213_Gigi's CPMA_v2.1 

Survivor Stories

NPAD Montage V3.1

Here are just a few of the faces that fully recovered from parvovirus after receiving lifesaving CPMA treatment. 

Cookie, an 8-week-old pitbull mix puppy from California, was the first puppy to be treated with CPMA. 

Dolly, an 8-week-old mixed breed puppy from Sugar Land, Texas received CPMA at the First Colony Veterinary Clinic.

Patrick, a 10-week-old terrier mix from Valley Stream, New York spent two days at BARRK Animal Rescue after being treated with CPMA.

Beatrix, a 3-month-old dalmatian from Glendale, Arizona .

Buster, a 12-week-old mixed breed from Waynesboro, Georgia spent four days in the Burke County Animal Hospital.

Luna, a 10-week-old rat terrier from St. Petersburg, Florida was given CPMA and after receiving the treatment, was eating, gaining weight and steadily improving. Two days later, she made a full recovery. 

Similarly, Mono, a 2-month-old mixed breed who arrived at Paws Chicago after staff was told he required immediate help or face euthanasia; Mono tested positive for parvo and immediately received CPMA. Three days post-treatment, he was up running around.

To learn more about CPMA and report a parvo outbreak or learn which clinics near you carry CPMA, visit ParvoTrack.com.

Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates.
©2025 Elanco or its affiliates. PM-US-25-0730

ABOUT ELANCO
Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With 70 years of animal health heritage, we are committed to breaking boundaries and going beyond to help our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our Elanco Healthy Purpose™ sustainability pillars – all to advance the health of animals, people, the planet and our enterprise. Learn more at www.elanco.com.

[1] Elanco Animal Health. Market Data on File.
[2] Elanco Animal Health. Industry Data on File. 
[3] Elanco Animal Health. Data on File. 
[4] Sykes, JE. Canine Parvovirus Infections and Other Viral Enteritides. Canine and Feline Infectious Diseases. 2014:141-151


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.